Barrington Research Maintains Outperform on Haemonetics, Maintains $108 Price Target
Barrington Maintains Haemonetics(HAE.US) With Buy Rating, Maintains Target Price $108
Buy Rating Affirmed for Haemonetics With Promising Growth in Hospital Segment and Strong Plasma Market Position
Haemonetics Initiated at Buy by CL King
Haemonetics Analyst Ratings
C.L. King Initiates Haemonetics(HAE.US) With Buy Rating, Announces Target Price $116
BofA Securities Initiates Haemonetics(HAE.US) With Hold Rating, Announces Target Price $85
Haemonetics Price Target Announced at $85.00/Share by B of A Securities
BTIG Initiates Haemonetics(HAE.US) With Buy Rating, Announces Target Price $112
Haemonetics Analyst Ratings
Citi Maintains Haemonetics(HAE.US) With Hold Rating, Cuts Target Price to $85
Haemonetics Analyst Ratings
JMP Securities Reiterates Market Outperform on Haemonetics, Maintains $125 Price Target
Haemonetics Corporation: Strong Growth and Innovation Justify a Buy Rating
Haemonetics Analyst Ratings
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $108
Haemonetics: A Stable Outlook With Promising Profitability Targets Justifies Buy Rating
Haemonetics Analyst Ratings
Haemonetics Positioned for Strong Growth: Buy Rating Justified Amidst Operational and Financial Optimism
Haemonetics Analyst Ratings